Brief: Nabriva Therapeutics Posts Q3 Revenue Of $8.9 Million
09/11/2021 21:54
Nov 9 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* NABRIVA THERAPEUTICS REPORTS THIRD QUARTER 2021 FINANCIAL
RESULTS AND PROVIDES A CORPORATE UPDATE
* Q3 REVENUE $8.9 MILLION
* CASH RUNWAY EXTENDED TO SUBSTANTIALLY THROUGH Q2 2022
* QTRLY REVENUES OF $8.9 MILLION INCREASED 8% SEQUENTIALLY
VERSUS
Q2 2021
Source text for Eikon: ID:nGNXq8VKW
Further company coverage: NBRV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update